港股異動 | 海吉亞醫療(6078.HK)漲7% 券商上調其今明兩年盈利預期
格隆匯4月4日丨海吉亞醫療(6078.HK)漲7%,報32.8港元,暫成交2913萬港元,總市值202億港元。天風證券報吿稱,維持海吉亞醫療“買入”評級,考慮到醫院業務盈利能力提升,以及公司全國擴張能力不斷兑現,根據2021年年報業績情況,2022/23年淨利潤預測由5.56/6.94億元上調至5.95/8.05億元。維持其“買入”評級;開源證券稱,公司核心醫院業務盈利能力穩步提升,內生外延持續加強腫瘤醫療服務網絡佈局。此外,新籤醫院方面,龍巖海吉亞和常熟海吉亞醫院預計於2024年建設完成。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.